AVE 0.00% 0.3¢ avecho biotechnology limited

just another cbd oil not worth a crumpet as a regulatory...

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 4,461 Posts.
    lightbulb Created with Sketch. 8612
    just another cbd oil not worth a crumpet as a regulatory approved cbd oil without any real market in unmet need ....
    lol...yer rightio then.

    https://au.investing.com/news/stock-market-news/fda-grants-orphan-drug-status-to-cardiols-heart-disease-drug-93CH-3119331

    The FDA's ODD is aimed at encouraging the development of treatments for rare diseases—those affecting fewer than 200,000 people in the U.S. The designation comes with benefits such as potential seven-year marketing exclusivity, fee waivers, and tax credits for clinical trials. Moreover, drugs with ODD can potentially be fast-tracked for regulatory review.

    up 48% overnight...wonder why?....lol
    red or black - the numbers are correct
    Last edited by Flectional: 16/02/24
 
watchlist Created with Sketch. Add AVE (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.